Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Interferon and Cytokine Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 10386858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

  1997cited by this paper
• Detection of serum interferon-alpha by dissociation-enhanced lanthanide fluoroimmunoassay. Studies of patients with acute viral and bacterial infections.

  1997cited by this paper
• Contributions of cloned type I interferon receptor subunits to differential ligand binding 1

  1997cited by this paper
• The neglected role of type I interferon in the T-cell response: implications for its clinical use.

  1996cited by this paper
• Nomenclature of the Human Interferon Genesa

  1996cited by this paper
• Why Do So Many Cancer Patients Fail to Respond to Interferon Therapy?

  1996cited by this paper
• Undetectable interferon-alpha serum levels in a patient with atopic dermatitis.

  1995cited by this paper
• Serum levels of interferon-alpha and -gamma in acute and chronic hepatitis B virus infection.

  1995cited by this paper
• Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders.

  1994cited by this paper
• Soluble interferon-alpha receptor molecules are present in body fluids.

  1992cited by this paper
• Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions.

  1992cited by this paper
• Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome.

  1992cited by this paper
• Immunoreactive circulating alpha-interferon in rheumatoid arthritis.

  1990cited by this paper
• Serum levels of alpha-interferon and gamma-interferon in patients with acute and chronic viral hepatitis.

  1989cited by this paper
• Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days.

  1988cited by this paper
• Interferon-alpha in sera of HIV-infected patients.

  1987cited by this paper
• Interferon messenger RNA is produced constitutively in the organs of normal individuals.

  1987cited by this paper
• A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients.

  1986cited by this paper
• Interferon from 1981 to 1986.

  1986cited by this paper
• The interferon system as an integral part of the defense system against infections.

  1986cited by this paper
• Unusual apparently constitutive interferons and antagonists in human placental blood.

  1985cited by this paper
• Inactivation of Interferon by Serum and Synovial Fluids 1

  1985cited by this paper
• Effect of exercise on plasma interferon levels.

  1985cited by this paper
• Application of an objective biological assay of human interferons to clinical specimens and a survey of a normal population

  1985cited by this paper
• Radioimmunoassay of leukocyte (alpha) interferon and its application to some clinical conditions.

  1984cited by this paper
• Effects of cloned interferon alpha 2 in normal volunteers: febrile reactions and changes in circulating corticosteroids and trace metals

  1983cited by this paper
• Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon.

  1982cited by this paper
• An immunoradiometric assay of serum interferon using a monoclonal antibody.

  1982cited by this paper
• Presence of interferon in acute- and convalescent-phase sera of humans with influenza or influenza-like illness of undetermined etiology.

  1982cited by this paper
• [Interferon: A greatly simplified immuno enzyme determination with two monoclonal antibodies].

  1982cited by this paper
• Evaluation of the human interferon system in viral disease.

  1981cited by this paper

• Expression signatures with specificity for type I and II IFN response and relevance for autoimmune diseases and cancer

  2025cites this paper
• Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE

  2024cites this paper
• Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5+ dermatomyositis

  2023cites this paper
• Non‐selective dampening of the host immune response after hepatitis C clearance and its association with circulating chemokine and endotoxin levels

  2023cites this paper
• Differences and similarities in cytokine profiles of macrophage activation syndrome in systemic lupus erythematosus and adult-onset Still’s disease

  2023cites this paper
• 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

  2023cites this paper
• Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider

  2023cites this paper
• Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE

  2023cites this paper
• Assessment of type I interferon signatures in undifferentiated inflammatory diseases: A Japanese multicenter experience

  2022cites this paper
• Design and validation of an immuno-PCR assay for IFN-α2b quantification in human plasma.

  2019cites this paper
• Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases.

  2019cites this paper
• High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus

  2019cites this paper
• Monitoring Disease Activity in Systemic Lupus Erythematosus With Single‐Molecule Array Digital Enzyme‐Linked Immunosorbent Assay Quantification of Serum Interferon‐α

  2019cites this paper
• CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus

  2018cites this paper
• Type I interferon in rheumatic diseases

  2018cites this paper
• Interferons, B Cells and Neutrophils: Innate and Adaptive Allies in Systemic Lupus Erythematosus

  2018cites this paper
• Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.

  2016cites this paper
• Relapsing-Remitting Multiple Sclerosis Regulation of Th 17 Responses in Patients in the β The Role of Endogenous IFN -

  2014cites this paper
• The Role of Endogenous IFN-β in the Regulation of Th17 Responses in Patients with Relapsing-Remitting Multiple Sclerosis

  2014cites this paper
• Genetic Analysis of the Pathogenic Molecular Sub-phenotype Interferon Alpha Identifies Multiple Novel Loci Involved in Systemic Lupus Erythematosus

  2014cites this paper
• The 9p21 locus does not affect risk of coronary artery disease through induction of type 1 interferons.

  2013cites this paper
• Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4+ T cells

  2013cites this paper
• Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

  2012cites this paper
• Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.

  2012cites this paper
• IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus

  2012cites this paper
• Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.

  2012cites this paper
• Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.

  2011cites this paper
• IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus

  2011cites this paper
• Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

  2011cites this paper
• Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis

  2010cites this paper
• Tartrate resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature

  2010cites this paper
• Interferon-alpha: a therapeutic target in systemic lupus erythematosus.

  2010cites this paper
• Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

  2009cites this paper
• Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab

  2009cites this paper
• The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome.

  2009cites this paper
• F.57. Elevated Serum Interferon Alpha Activity in Juvenile Dermatomyositis: Associations with Disease Activity at Diagnosis and After 36 Months of Therapy

  2009cites this paper
• Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.

  2008cites this paper
• High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.

  2007cites this paper
• High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus

  2007cites this paper
• [Use of Getah virus for antiviral assay of human interferon].

  2005cites this paper
• Heterophile antibodies masquerade as interferon-alpha in subjects with new-onset type 1 diabetes.

  2004cites this paper
• Interferon-alpha-like biological activity in human seminal plasma, follicular fluid, embryo culture medium, amniotic fluid and fetal blood.

  2003cites this paper
• Atopic Phenotype in Children Is Associated with Decreased Virus-Induced Interferon-α Release

  2002cites this paper
• Identification of a novel dendritic cell‐like subset of CD64+ / CD16+ blood monocytes

  2001cites this paper
• Integration of adeno‐associated virus 2 DNA in human MKR melanoma cells induces a peptide with oncosuppressive properties

  2001cites this paper
• Human T cells elicit IFN-alpha secretion from dendritic cells following cell to cell interactions.

  2000cites this paper
• The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs.

  2000cites this paper
• Human T cells elicit IFN‐α secretion from dendritic cells following cell to cell interactions

  2000cites this paper
• With Relapsing-remitting Multiple Sclerosis Regulation of Th17 Responses in Patients in the Β the Role of Endogenous Ifn

  year unknowncites this paper
• With Relapsing-remitting Multiple Sclerosis Regulation of Th17 Responses in Patients in the Β the Role of Endogenous Ifn

  year unknowncites this paper